Clinical trials
Hyperlipoproteinemia Type II trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2018 | 1 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 7 |
| Completed | 5 |
| Not yet recruiting | 2 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 4 |
| Novartis Pharmaceuticals | 2 |
| Children's Hospital of Fudan University | 1 |
| China Cardiovascular Association | 1 |
| Hasten Biopharmaceutical Co., Ltd. | 1 |
| Innovent Biologics (Suzhou) Co. Ltd. | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| Merck Sharp & Dohme LLC | 1 |
| NewAmsterdam Pharma | 1 |
| RenJi Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperlipoproteinemia Type II | 17 |
| Hypercholesterolemia | 6 |
| Dyslipidemias | 5 |
| Aortic Valve Stenosis | 2 |
| Cardiovascular Diseases | 2 |
| Heart Failure | 2 |
| Hyperlipidemias | 2 |
| Atherosclerosis | 1 |
| Homozygous Familial Hypercholesterolemia | 1 |
| Hypertriglyceridemia | 1 |
Trials
Showing 76 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.